

# Teresa GÃ³mez-Isla

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6212876/publications.pdf>

Version: 2024-02-01

40  
papers

7,684  
citations

201575

27  
h-index

345118

36  
g-index

40  
all docs

40  
docs citations

40  
times ranked

8169  
citing authors

#	ARTICLE	IF	CITATIONS
1	Longitudinal Changes in Neuropsychiatric Symptoms: Impact of Discrepancy in Everyday Preferences Between Persons With Cognitive Impairment and Their Care Partners. <i>American Journal of Geriatric Psychiatry</i> , 2022, 30, 619-623.	0.6	4
2	Novel genetic variants in <i>MAPT</i> and alterations in tau phosphorylation in amyotrophic lateral sclerosis postmortem motor cortex and cerebrospinal fluid. <i>Brain Pathology</i> , 2022, 32, e13035.	2.1	15
3	Lesions without symptoms: understanding resilience to Alzheimer disease neuropathological changes. <i>Nature Reviews Neurology</i> , 2022, 18, 323-332.	4.9	29
4	Changes in glial cell phenotypes precede overt neurofibrillary tangle formation, correlate with markers of cortical cell damage, and predict cognitive status of individuals at Braak III-IV stages. <i>Acta Neuropathologica Communications</i> , 2022, 10, 72.	2.4	5
5	Isoform-selective decrease of glycogen synthase kinase-3-beta (GSK-3 $\beta$ ) reduces synaptic tau phosphorylation, transcellular spreading, and aggregation. <i>IScience</i> , 2021, 24, 102058.	1.9	16
6	Editorial: Understanding factors that, beyond plaques and tangles, contribute to the heterogeneity of Alzheimer disease and implications for the development of biomarkers and design of interventions. <i>Current Opinion in Neurology</i> , 2021, 34, 226-227.	1.8	0
7	The cortical origin and initial spread of medial temporal tauopathy in Alzheimer's disease assessed with positron emission tomography. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	111
8	Aducanumab for Alzheimer disease: the amyloid hypothesis moves from bench to bedside. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	21
9	The Challenge of Defining Alzheimer Disease Based on Biomarkers in the Absence of Symptoms. <i>JAMA Neurology</i> , 2019, 76, 1143.	4.5	4
10	Neuropathologic correlates of amyloid and dopamine transporter imaging in Lewy body disease. <i>Neurology</i> , 2019, 93, e476-e484.	1.5	23
11	[18F]-AV-1451 binding profile in chronic traumatic encephalopathy: a postmortem case series. <i>Acta Neuropathologica Communications</i> , 2019, 7, 164.	2.4	33
12	Associations between baseline amyloid, sex, and APOE on subsequent tau accumulation in cerebrospinal fluid. <i>Neurobiology of Aging</i> , 2019, 78, 178-185.	1.5	54
13	Autoradiography validation of novel tau PET tracer [F-18]-MK-6240 on human postmortem brain tissue. <i>Acta Neuropathologica Communications</i> , 2019, 7, 37.	2.4	105
14	Distinct cytokine profiles in human brains resilient to Alzheimer's pathology. <i>Neurobiology of Disease</i> , 2019, 121, 327-337.	2.1	79
15	18F-Flortaucipir Binding in Choroid Plexus: Related to Race and Hippocampus Signal. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 1691-1702.	1.2	67
16	White matter abnormalities and cognition in patients with conflicting diagnoses and CSF profiles. <i>Neurology</i> , 2018, 90, e1461-e1469.	1.5	11
17	Association of In Vivo [ <sup>18</sup> F]AV-1451 Tau PET Imaging Results With Cortical Atrophy and Symptoms in Typical and Atypical Alzheimer Disease. <i>JAMA Neurology</i> , 2017, 74, 427.	4.5	236
18	[F-18]-AV-1451 binding correlates with postmortem neurofibrillary tangle Braak staging. <i>Acta Neuropathologica</i> , 2017, 134, 619-628.	3.9	77

#	ARTICLE	IF	CITATIONS
19	Pathological correlations of [ <sup>18</sup> F]-AV-1451 imaging in non-Alzheimer tauopathies. <i>Annals of Neurology</i> , 2017, 81, 117-128.	2.8	174
20	Alzheimer's Disease Biomarkers and Future Decline in Cognitive Normal Older Adults. <i>Journal of Alzheimer's Disease</i> , 2017, 60, 1451-1459.	1.2	80
21	Lessons learned about [ <sup>18</sup> F]-AV-1451 off-target binding from an autopsy-confirmed Parkinson's case. <i>Acta Neuropathologica Communications</i> , 2017, 5, 75.	2.4	85
22	Amyloid structure exhibits polymorphism on multiple length scales in human brain tissue. <i>Scientific Reports</i> , 2016, 6, 33079.	1.6	48
23	Episodic memory of odors stratifies Alzheimer biomarkers in normal elderly. <i>Annals of Neurology</i> , 2016, 80, 846-857.	2.8	36
24	Tau positron emission tomographic imaging in aging and early Alzheimer disease. <i>Annals of Neurology</i> , 2016, 79, 110-119.	2.8	778
25	Temporal T807 binding correlates with CSF tau and phospho-tau in normal elderly. <i>Neurology</i> , 2016, 87, 920-926.	1.5	86
26	In Vivo Tau, Amyloid, and Gray Matter Profiles in the Aging Brain. <i>Journal of Neuroscience</i> , 2016, 36, 7364-7374.	1.7	153
27	IC-P-162: Entorhinal, parahippocampal, and inferior temporal F18-T807 SUVR correlates with CSF total tau and tau T181P in cognitively normal elderly. , 2015, 11, P109-P109.		2
28	Validating novel tau positron emission tomography tracer [ <sup>18</sup> F]-AV-1451 (T807) on postmortem brain tissue. <i>Annals of Neurology</i> , 2015, 78, 787-800.	2.8	535
29	O4-01-04: Entorhinal, parahippocampal, and inferior temporal F18-T807 SUVR correlates with CSF total tau and tau T181P in cognitively normal elderly. , 2015, 11, P267-P267.		1
30	Subjective Cognitive Concerns and Neuropsychiatric Predictors of Progression to the Early Clinical Stages of Alzheimer Disease. <i>American Journal of Geriatric Psychiatry</i> , 2014, 22, 1642-1651.	0.6	167
31	Dissecting phenotypic traits linked to human resilience to Alzheimer's pathology. <i>Brain</i> , 2013, 136, 2510-2526.	3.7	294
32	Stable Size Distribution of Amyloid Plaques Over the Course of Alzheimer Disease. <i>Journal of Neuropathology and Experimental Neurology</i> , 2012, 71, 694-701.	0.9	41
33	Reactive Glia not only Associates with Plaques but also Parallels Tangles in Alzheimer's Disease. <i>American Journal of Pathology</i> , 2011, 179, 1373-1384.	1.9	379
34	Neuropathology of Alzheimer's Disease. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2008, 89, 233-243.	1.0	44
35	Use of structural magnetic resonance imaging to predict who will get Alzheimer's disease. <i>Annals of Neurology</i> , 2000, 47, 430-439.	2.8	607
36	Use of structural magnetic resonance imaging to predict who will get Alzheimer's disease. , 2000, 47, 430.		14

#	ARTICLE	IF	CITATIONS
37	Stereology: A Practical Primer for Neuropathology. Journal of Neuropathology and Experimental Neurology, 1998, 57, 305-310.	0.9	77
38	Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Annals of Neurology, 1997, 41, 17-24.	2.8	1,243
39	Profound Loss of Layer II Entorhinal Cortex Neurons Occurs in Very Mild Alzheimer's Disease. Journal of Neuroscience, 1996, 16, 4491-4500.	1.7	1,570
40	Clinical and pathological correlates of apolipoprotein E 4 in Alzheimer's disease. Annals of Neurology, 1996, 39, 62-70.	2.8	380